NO20050450L - Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft - Google Patents
Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreftInfo
- Publication number
- NO20050450L NO20050450L NO20050450A NO20050450A NO20050450L NO 20050450 L NO20050450 L NO 20050450L NO 20050450 A NO20050450 A NO 20050450A NO 20050450 A NO20050450 A NO 20050450A NO 20050450 L NO20050450 L NO 20050450L
- Authority
- NO
- Norway
- Prior art keywords
- combination
- cancer
- radiotherapy
- inhibitor
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 3
- 108091008605 VEGF receptors Proteins 0.000 title 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000001959 radiotherapy Methods 0.000 title 1
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 title 1
- 241001465754 Metazoa Species 0.000 abstract 2
- 230000001772 anti-angiogenic effect Effects 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000005865 ionizing radiation Effects 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 230000002792 vascular Effects 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0218525A GB0218525D0 (en) | 2002-08-09 | 2002-08-09 | Combination therapy |
| GB0307560A GB0307560D0 (en) | 2003-04-02 | 2003-04-02 | Combination therapy |
| PCT/GB2003/003388 WO2004014383A1 (en) | 2002-08-09 | 2003-08-05 | Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20050450L true NO20050450L (no) | 2005-05-02 |
Family
ID=31716921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20050450A NO20050450L (no) | 2002-08-09 | 2005-01-26 | Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20050222183A1 (enExample) |
| EP (1) | EP1534287A1 (enExample) |
| JP (1) | JP2006502132A (enExample) |
| KR (1) | KR20050056190A (enExample) |
| CN (1) | CN1313094C (enExample) |
| AU (1) | AU2003249000B2 (enExample) |
| BR (1) | BR0313116A (enExample) |
| CA (1) | CA2495487A1 (enExample) |
| IL (1) | IL166522A0 (enExample) |
| MX (1) | MXPA05001458A (enExample) |
| NO (1) | NO20050450L (enExample) |
| NZ (1) | NZ537753A (enExample) |
| WO (1) | WO2004014383A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1676845B1 (en) | 1999-11-05 | 2008-06-11 | AstraZeneca AB | New quinazoline derivatives |
| GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| EP1274692B1 (en) * | 2000-04-07 | 2006-08-02 | AstraZeneca AB | Quinazoline compounds |
| GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
| NZ534171A (en) * | 2002-02-01 | 2007-06-29 | Astrazeneca Ab | Quinazoline compounds for the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
| GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| NZ539408A (en) | 2002-11-04 | 2007-09-28 | Astrazeneca Ab | Quinazoline derivatives as SRC tyrosine kinase inhibitors for treating solid tumours |
| CA2514227C (en) * | 2003-02-13 | 2011-08-09 | Astrazeneca Ab | Combination therapy of zd6474 with 5-fu or/and cpt-11 |
| GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
| BRPI0412426A (pt) * | 2003-07-10 | 2006-09-05 | Astrazeneca Ab | uso da zd6474 ou de um sal farmaceuticamente aceitável da mesma e de um agente antitumoral de platina, composição farmacêutica, kit, e método para a produção de um efeito antiangiogênico e/ou redutor de permeabilidade vascular em um animal de sangue quente |
| BRPI0516052A (pt) * | 2004-09-27 | 2008-08-19 | Astrazeneca Ab | uso de zd6474 ou de um sal farmaceuticamente aceitável do mesmo e de imatinib, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente |
| GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
| GB0519879D0 (en) | 2005-09-30 | 2005-11-09 | Astrazeneca Ab | Chemical process |
| EP1971338B8 (en) * | 2005-12-22 | 2011-09-21 | AstraZeneca AB | Combination of zd6474 and pemetrexed |
| JP4945133B2 (ja) * | 2006-01-19 | 2012-06-06 | 富士フイルムＲｉファーマ株式会社 | ４−フェノキシキナゾリン誘導体放射性化合物 |
| US20100092466A1 (en) * | 2006-09-29 | 2010-04-15 | Anderson Joseph Ryan | Combination of zd6474 and bevacizumab for cancer therapy |
| US20080190689A1 (en) * | 2007-02-12 | 2008-08-14 | Ballard Ebbin C | Inserts for engine exhaust systems |
| WO2009118560A1 (en) * | 2008-03-28 | 2009-10-01 | Astrazeneca Ab | Combination therapy 038 |
| CN106317022A (zh) * | 2015-06-25 | 2017-01-11 | 中美华世通生物医药科技（武汉）有限公司 | 化合物的制备方法和用途 |
| CN106397401B (zh) * | 2016-08-30 | 2018-11-13 | 山东罗欣药业集团股份有限公司 | 一种抗癌药物的晶体化合物及其制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1676845B1 (en) * | 1999-11-05 | 2008-06-11 | AstraZeneca AB | New quinazoline derivatives |
-
2003
- 2003-08-05 EP EP03784247A patent/EP1534287A1/en not_active Withdrawn
- 2003-08-05 CN CNB038191016A patent/CN1313094C/zh not_active Expired - Fee Related
- 2003-08-05 KR KR1020057002082A patent/KR20050056190A/ko not_active Ceased
- 2003-08-05 CA CA002495487A patent/CA2495487A1/en not_active Abandoned
- 2003-08-05 JP JP2004527017A patent/JP2006502132A/ja active Pending
- 2003-08-05 BR BR0313116-5A patent/BR0313116A/pt not_active IP Right Cessation
- 2003-08-05 US US10/523,832 patent/US20050222183A1/en not_active Abandoned
- 2003-08-05 NZ NZ537753A patent/NZ537753A/en unknown
- 2003-08-05 AU AU2003249000A patent/AU2003249000B2/en not_active Ceased
- 2003-08-05 MX MXPA05001458A patent/MXPA05001458A/es unknown
- 2003-08-05 WO PCT/GB2003/003388 patent/WO2004014383A1/en not_active Ceased
-
2005
- 2005-01-26 NO NO20050450A patent/NO20050450L/no not_active Application Discontinuation
- 2005-01-26 IL IL16652205A patent/IL166522A0/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1674905A (zh) | 2005-09-28 |
| NZ537753A (en) | 2008-04-30 |
| MXPA05001458A (es) | 2005-06-06 |
| CA2495487A1 (en) | 2004-02-19 |
| JP2006502132A (ja) | 2006-01-19 |
| IL166522A0 (en) | 2006-01-15 |
| AU2003249000B2 (en) | 2007-04-05 |
| AU2003249000A1 (en) | 2004-02-25 |
| EP1534287A1 (en) | 2005-06-01 |
| CN1313094C (zh) | 2007-05-02 |
| KR20050056190A (ko) | 2005-06-14 |
| BR0313116A (pt) | 2005-07-05 |
| US20050222183A1 (en) | 2005-10-06 |
| WO2004014383A1 (en) | 2004-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20050450L (no) | Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft | |
| NO20071426L (no) | Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib | |
| DK1551409T3 (da) | Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer | |
| DK1373215T3 (da) | Gelanamycinderivater egnet til behandling af cancer | |
| CY1111565T1 (el) | Θεραπεια συνδυασμου του zd6474 με 5-fu και/ή cpt-11 | |
| NO20072167L (no) | Kombinasjon omfattende ZD6474 og et antiandrogen | |
| NO20050528L (no) | Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft | |
| NO20071428L (no) | Kombinasjon inneholdende ZD6474 og Imatinib | |
| AR037346A1 (es) | Terapia de combinacion | |
| DE602004022285D1 (de) | Verfahren zur behandlung von erkrankungen mit hsp90-hemmenden mitteln in kombination mit antimitotika | |
| DE602004011051D1 (de) | Verfahren zur behandlung von krankheiten mit hsp90-hemmenden mitteln in kombination mit antimetaboliten | |
| EA200801731A1 (ru) | Составы и способы лечения тробмоцитемии | |
| ATE500832T1 (de) | Kombination von zd6474 und pemetrexed | |
| NO20076657L (no) | Kombinasjonsterapi av cancer med AZD2171 og gemcitabin | |
| DE50100833D1 (de) | Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen | |
| NO20056170L (no) | Kreftkombinasjonsterapi omfattende AZD2171 of ZD1839 | |
| NO20064753L (no) | Kombinasjonsterapi | |
| DE60334289D1 (de) | Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen | |
| NO20051601L (no) | Kombinasjonsterapi med gemcitabin og zd6126 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |